Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
11
08
2020
accepted:
02
11
2020
pubmed:
13
2
2021
medline:
15
5
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
Thoracic malignancies are associated with high mortality rates. Conventional therapy for many of the patients with thoracic malignancies is obviated by a high incidence of locoregional recurrence and distant metastasis. Fortunately, developments in immunotherapy provide effective strategies for both local and systemic treatments that have rapidly advanced during the last decade. One promising approach to cancer immunotherapy is to use oncolytic viruses, which have the advantages of relatively high tumor specificity, selective replication-mediated oncolysis, enhanced antigen presentation, and potential for delivery of immunogenic payloads such as cytokines, with subsequent elicitation of effective antitumor immunity. Several oncolytic viruses including adenovirus, coxsackievirus B3, herpes virus, measles virus, reovirus, and vaccinia virus have been developed and applied to thoracic cancers in preclinical murine studies and clinical trials. This review discusses the current state of oncolytic virotherapy in lung cancer, esophageal cancer, and metastatic malignant pleural effusions and considers its potential as an emergent therapeutic for these patients.
Identifiants
pubmed: 33575873
doi: 10.1245/s10434-020-09477-4
pii: 10.1245/s10434-020-09477-4
pmc: PMC8043873
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2715-2727Subventions
Organisme : Division of Cancer Prevention, National Cancer Institute
ID : T32CA113263-11
Organisme : Office of Research, Health Sciences, University of Pittsburgh
ID : Dean's Faculty Advancement Award
Organisme : U.S. Department of Defense
ID : CDMRP KC180267
Organisme : CSR NIH HHS
ID : R01CA206012
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA113263
Pays : United States
Organisme : CSR NIH HHS
ID : 1R01 CA181450-01
Pays : United States
Références
Moore AE. The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. Cancer. 1949;2:525–34. Epub 1949/05/01. https://doi.org/10.1002/1097-0142(194905)2:3%3c525::aid-cncr2820020317%3e3.0.co;2-o . PubMed PMID: 18131412.
Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3:841–9. https://doi.org/10.1001/jamaoncol.2016.2064 . PubMed PMID: 27441411.
doi: 10.1001/jamaoncol.2016.2064
pubmed: 27441411
Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18:498–513. https://doi.org/10.1038/s41577-018-0014-6 . PubMed PMID: 29743717.
doi: 10.1038/s41577-018-0014-6
pubmed: 29743717
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–8. https://doi.org/10.1200/jco.2014.58.3377 . PubMed PMID: 26014293.
doi: 10.1200/JCO.2014.58.3377
pubmed: 26014293
Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016;4:53. https://doi.org/10.1186/s40425-016-0158-5 . PubMed PMID: 27660707; PMCID: PMC5029010.
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunol Ther Cancer. 2020;8:e000337. https://doi.org/10.1136/jitc-2019-000337 .
doi: 10.1136/jitc-2019-000337
Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10:292–303. Epub 2003/02/22. https://doi.org/10.1038/sj.gt.3301885 . 3301885 [pii]. PubMed PMID: 12595888.
Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, et al. Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol. 2016;23:4169–77. https://doi.org/10.1245/s10434-016-5286-0 . PubMed PMID: 27342831; PMCID: PMC5090012.
doi: 10.1245/s10434-016-5286-0
Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng. 2004;23:1666–70. PubMed PMID: 15601557.
pubmed: 15601557
Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets. 2007;7:141–8. https://doi.org/10.2174/156800907780058817 . PubMed PMID: 17346105.
doi: 10.2174/156800907780058817
pubmed: 17346105
O’Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004;6:611–23. https://doi.org/10.1016/j.ccr.2004.11.012 . PubMed PMID: 15607965.
doi: 10.1016/j.ccr.2004.11.012
pubmed: 15607965
Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D. The advent of oncolytic virotherapy in oncology: The Rigvir
Doniņa S, Strēle I, Proboka G, Auziņš J, Alberts P, Jonsson B, et al. Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015;25:421–6. Epub 2015/07/21. https://doi.org/10.1097/cmr.0000000000000180 . PubMed PMID: 26193376; PMCID: PMC4560272.
Alberts, P., Olmane, E., Brokāne, L., Krastiņa, Z., Romanovska, M., Kupčs, K., et al. Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. APMIS. 2016;124(10), 896–904. Epub 2016/07/26. https://doi.org/10.1111/apm.12576 . PubMed PMID: 27457663.
Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta. 2008;1785:217–31. Epub 2008/03/11. doi: S0304-419X(08)00004-8 [pii]. https://doi.org/10.1016/j.bbcan.2008.02.001 . PubMed PMID: 18328829.
Dash AS, Patel MR. Viroimmunotherapy of thoracic cancers. Biomedicines. 2017;5:2. https://doi.org/10.3390/biomedicines5010002 . PubMed PMID: 28536345.
doi: 10.3390/biomedicines5010002
Patel MR. Immunotherapy for thoracic oncology gone viral. Immunotherapy. 2018;10:383–90. Epub 2018/02/24. https://doi.org/10.2217/imt-2017-0148 . PubMed PMID: 29473469.
Ahmad Z, Kratzke RA. Novel oncolytic viral therapies in patients with thoracic malignancies. Oncolytic Virother. 2016;6:1–9. https://doi.org/10.2147/ov.s116012 . PubMed PMID: 28053943.
doi: 10.2147/OV.S116012
pubmed: 28053943
pmcid: 5189707
Pease DF, Kratzke RA. Oncolytic viral therapy for mesothelioma. Front Oncol. 2017;7:179. https://doi.org/10.3389/fonc.2017.00179 . PubMed PMID: 28884088; PMCID: PMC5573749.
doi: 10.3389/fonc.2017.00179
Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 2018;19:e161–e72. https://doi.org/10.1016/s1470-2045(18)30100-1 . PubMed PMID: 29508763.
doi: 10.1016/S1470-2045(18)30100-1
pubmed: 29508763
Remy-Ziller C, Thioudellet C, Hortelano J, Gantzer M, Nourtier V, Claudepierre MC, et al. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-betaGal and MVA-MUC1 (TG4010) in a murine tumor model. Hum Vaccin Immunother. 2018;14:140–5. Epub 2017/09/20. https://doi.org/10.1080/21645515.2017.1373921 . PubMed PMID: 28925793; PMCID: PMC5791558.
Gurusamy D, Henning AN, Yamamoto TN, Yu Z, Zacharakis N, Krishna S, et al. Multi-phenotype CRISPR-Cas9 screen identifies p38 kinase as a target for adoptive immunotherapies. Cancer Cell. 2020;37:818–33.e9. https://doi.org/10.1016/j.ccell.2020.05.004 . PubMed PMID: 32516591.
doi: 10.1016/j.ccell.2020.05.004
Ren D, Qin G, Zhao J, Sun Y, Zhang B, Li D, et al. Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer. Am J Cancer Res. 2020;10:2851–64. PubMed PMID: 33042621.
pubmed: 33042621
pmcid: 7539786
Huang A, Garraway LA, Ashworth A, Weber B. Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Discov. 2020;19:23–38. https://doi.org/10.1038/s41573-019-0046-z . PubMed PMID: 31712683.
doi: 10.1038/s41573-019-0046-z
pubmed: 31712683
Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines, and finally apoptosis. Int J Oncol. 2002;21:85–93. Epub 2002/06/14. https://doi.org/10.3892/ijo.21.1.85 . PubMed PMID: 12063554.
Ma J, Ramachandran M, Jin C, Quijano-Rubio C, Martikainen M, Yu D, Essand M. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death Dis. 2020;11:48. Epub 2020/01/24. https://doi.org/10.1038/s41419-020-2236-3 . PubMed PMID: 31969562; PMCID: PMC6976683.
Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–555. https://doi.org/10.1038/s41586-019-1922-8 . PubMed PMID: 31942075.
doi: 10.1038/s41586-019-1922-8
pubmed: 31942075
Hou W, Sampath P, Rojas JJ, Thorne SH. Oncolytic virus-mediated targeting of PGE2 in the tumor alters the immune status and sensitizes established and resistant tumors to immunotherapy. Cancer Cell. 2016;30:108–19. Epub 2016/07/05. https://doi.org/10.1016/j.ccell.2016.05.012 . PubMed PMID: 27374223; PMCID: PMC4962335.
Di Pilato M, Mejias-Perez E, Zonca M, Perdiguero B, Gomez CE, Trakala M, et al. NFkappaB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses. Proc Natl Acad Sci U S A. 2015;112:E1333–42. Epub 2015/03/06. https://doi.org/10.1073/pnas.1424341112 . PubMed PMID: 25739961; PMCID: PMC4371968.
Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019;7:6. Epub 2019/01/11. https://doi.org/10.1186/s40425-018-0495-7 . PubMed PMID: 30626434; PMCID: PMC6325819.
Smith CL, Mirza F, Pasquetto V, Tscharke DC, Palmowski MJ, Dunbar PR, et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara J Immunol. 2005;175:8431–7. Epub 2005/12/13. https://doi.org/10.4049/jimmunol.175.12.8431 . PubMed PMID: 16339586.
Tsang KY, Palena C, Yokokawa J, Arlen PM, Gulley JL, Mazzara GP, et al. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Clin Cancer Res. 2005;11:1597–607. Epub 2005/03/05. https://doi.org/10.1158/1078-0432.ccr-04-1609 . PubMed PMID: 15746065.
Ylosmaki E, Malorzo C, Capasso C, Honkasalo O, Fusciello M, Martins B, et al. Personalized cancer vaccine platform for clinically relevant oncolytic enveloped viruses. Mol Ther. 2018;26:2315–25. Epub 2018/07/15. https://doi.org/10.1016/j.ymthe.2018.06.008 . PubMed PMID: 30005865; PMCID: PMC6127500.
Vanderlugt CL, Begolka WS, Neville KL, Katz-Levy Y, Howard LM, Eagar TN, et al. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev. 1998;164:63–72. Epub 1998/10/31. https://doi.org/10.1111/j.1600-065x.1998.tb01208.x . PubMed PMID: 9795764.
Mahabadi N, Goizueta AA, Bordoni B. Anatomy, Thorax, Lung Pleura And Mediastinum. StatPearls [Internet]. Treasure Island (FL) 2020. PubMed PMID: 30085590.
Loo CP, Nelson NA, Lane RS, Booth JL, Loprinzi Hardin SC, Thomas A, et al. Lymphatic vessels balance viral dissemination and immune activation following cutaneous viral infection. Cell Rep. 2017;20:3176–87. Epub 2017/09/28. https://doi.org/10.1016/j.celrep.2017.09.006 . PubMed PMID: 28954233; PMCID: PMC5621787.
Bellini C, Ergaz Z, Boccardo F, Bellini T, Campisi CC, Bonioli E, Ramenghi LA. Dynamics of pleural fluid effusion and chylothorax in the fetus and newborn: role of the lymphatic system. Lymphology. 2013;46:75–84. PubMed PMID: 24354106.
pubmed: 24354106
Fourdrain A, Lafitte S, Iquille J, De Dominicis F, Havet E, Peltier J, et al. Lymphatic drainage of lung segments in the visceral pleura: a cadaveric study. Surg Radiol Anat. 2018;40:15–9. https://doi.org/10.1007/s00276-017-1910-3 . PubMed PMID: 28823002.
doi: 10.1007/s00276-017-1910-3
pubmed: 28823002
Soloff AC, Jones KE, Powers AA, Murthy P, Wang Y, Russell KL, et al. HMGB1 promotes myeloid egress and limits lymphatic clearance of malignant pleural effusions. Front Immunol. 2020;11:2027. https://doi.org/10.3389/fimmu.2020.02027 . PubMed PMID: 33013860; PMCID: PMC7498625.
doi: 10.3389/fimmu.2020.02027
pubmed: 33013860
pmcid: 7498625
Fend L, Yamazaki T, Remy C, Fahrner C, Gantzer M, Nourtier V, et al. Immune checkpoint blockade, immunogenic chemotherapy, or IFN-alpha blockade boost the local and abscopal effects of oncolytic virotherapy. Cancer Res. 2017;77:4146–57. Epub 2017/05/26. https://doi.org/10.1158/0008-5472.can-16-2165 . PubMed PMID: 28536278.
John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res. 2012;72:1651–60. Epub 2012/02/09. https://doi.org/10.1158/0008-5472.can-11-2788 . PubMed PMID: 22315352.
Durable Responses Achieved with AM0010. Cancer Discov. 2016;6(12):OF4. https://doi.org/10.1158/2159-8290.cd-nb2016-125 . PubMed PMID: 27803020.
Murthy P, Ekeke CN, Russell KL, Butler SC, Wang Y, Luketich JD, et al. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology. 2019;8:e1554969. https://doi.org/10.1080/2162402x.2018.1554969 . PubMed PMID: 30906651; PMCID: PMC6422374.
doi: 10.1080/2162402X.2018.1554969
Han J, Duan J, Bai H, Wang Y, Wan R, Wang X, et al. TCR repertoire diversity of peripheral PD-1(+)CD8(+) T cells predicts clinical outcomes after immunotherapy in patients with non-small cell lung cancer. Cancer Immunol Res. 2020;8:146–54. https://doi.org/10.1158/2326-6066.cir-19-0398 . PubMed PMID: 31719056.
doi: 10.1158/2326-6066.CIR-19-0398
pubmed: 31719056
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. https://doi.org/10.3322/caac.21442 . PubMed PMID: 29313949.
doi: 10.3322/caac.21442
pubmed: 29313949
Niemann J, Kuhnel F. Oncolytic viruses: adenoviruses. Virus Genes. 2017;53:700–6. https://doi.org/10.1007/s11262-017-1488-1 . PubMed PMID: 28702840.
doi: 10.1007/s11262-017-1488-1
pubmed: 28702840
Guan YS, Liu Y, Zou Q, He Q, La Z, Yang L, Hu Y. Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up. J Zhejiang Univ Sci B. 2009;10:331–40. https://doi.org/10.1631/jzus.b0820248 . PubMed PMID: 19434759; PMCID: PMC2676412.
doi: 10.1631/jzus.B0820248
Machiels J-P, Salazar R, Rottey S, Duran I, Dirix L, Geboes K, et al. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). J Immunother Cancer. 2019;7:20. https://doi.org/10.1186/s40425-019-0510-7 .
doi: 10.1186/s40425-019-0510-7
pubmed: 30691536
pmcid: 6348630
Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J Immunother Cancer. 2017;5:71. https://doi.org/10.1186/s40425-017-0277-7 . PubMed PMID: 28923104; PMCID: PMC5604344.
doi: 10.1186/s40425-017-0277-7
Gong J, Sachdev E, Mita AC, Mita MM. Clinical development of reovirus for cancer therapy: an oncolytic virus with immune-mediated antitumor activity. World J Methodol. 2016;6:25–42. https://doi.org/10.5662/wjm.v6.i1.25 . PubMed PMID: 27019795; PMCID: PMC4804250.
doi: 10.5662/wjm.v6.i1.25
Villalona-Calero MA, Lam E, Otterson GA, Zhao W, Timmons M, Subramaniam D, et al. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. Cancer. 2016;122:875–83. https://doi.org/10.1002/cncr.29856 . PubMed PMID: 26709987; PMCID: PMC5068485.
doi: 10.1002/cncr.29856
Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, et al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst. 2007;99:1623–33. https://doi.org/10.1093/jnci/djm198 . PubMed PMID: 17971529; PMCID: PMC5261858.
doi: 10.1093/jnci/djm198
Rudin CM, Poirier JT, Senzer NN, Stephenson J Jr, Loesch D, Burroughs KD, et al. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res. 2011;17:888–95. https://doi.org/10.1158/1078-0432.ccr-10-1706 . PubMed PMID: 21304001; PMCID: PMC5317273.
doi: 10.1158/1078-0432.CCR-10-1706
Schenk EL, Mandrekar SJ, Dy GK, Aubry MC, Tan AD, Dakhil SR, et al. A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) versus placebo for patients with extensive-stage SCLC (ES SCLC) who were stable or responding after at least four cycles of platinum-based chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study. J Thorac Oncol. 2020;15:110–9. https://doi.org/10.1016/j.jtho.2019.09.083 . PubMed PMID: 31605793.
doi: 10.1016/j.jtho.2019.09.083
pubmed: 31605793
Hernandez FP, Sandri-Goldin RM. Herpes simplex virus 1 regulatory protein ICP27 undergoes a head-to-tail intramolecular interaction. J Virol. 2010;84:4124–35. https://doi.org/10.1128/jvi.02319-09 . PubMed PMID: 20164236; PMCID: PMC2863791.
doi: 10.1128/JVI.02319-09
Li JM, Kao KC, Li LF, Yang TM, Wu CP, Horng YM, et al. MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells. Virol J. 2013;10:241. https://doi.org/10.1186/1743-422x-10-241 . PubMed PMID: 23876001; PMCID: PMC3734208.
doi: 10.1186/1743-422X-10-241
Zhang JF, Wei F, Wang HP, Li HM, Qiu W, Ren PK, et al. Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. J Exp Clin Cancer Res. 2010;29:52. https://doi.org/10.1186/1756-9966-29-52 . PubMed PMID: 20487549; PMCID: PMC2890545.
doi: 10.1186/1756-9966-29-52
Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y, et al. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther. 2009;8:980–7. https://doi.org/10.1158/1535-7163.mct-08-0901 . PubMed PMID: 19372571.
doi: 10.1158/1535-7163.MCT-08-0901
pubmed: 19372571
Garofalo M, Villa A, Rizzi N, Kuryk L, Rinner B, Cerullo V, et al. Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice. J Control Release. 2019;294:165–75. https://doi.org/10.1016/j.jconrel.2018.12.022 . PubMed PMID: 30557650.
doi: 10.1016/j.jconrel.2018.12.022
pubmed: 30557650
Yang Y, Xu H, Huang W, Ding M, Xiao J, Yang D, et al. Targeting lung cancer stem-like cells with TRAIL gene-armed oncolytic adenovirus. J Cell Mol Med. 2015;19:915–23. https://doi.org/10.1111/jcmm.12397 . PubMed PMID: 25683371; PMCID: PMC4420595.
doi: 10.1111/jcmm.12397
Miyamoto S, Inoue H, Nakamura T, Yamada M, Sakamoto C, Urata Y, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 2012;72:2609–21. Epub 2012/03/31. doi: 0008-5472.CAN-11-3185 [pii]. https://doi.org/10.1158/0008-5472.can-11-3185 . PubMed PMID: 22461509.
McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61:8751–7. Epub 2001/12/26. PubMed PMID: 11751395.
pubmed: 11751395
Wang LC, Lynn RC, Cheng G, Alexander E, Kapoor V, Moon EK, et al. Treating tumors with a vaccinia virus expressing IFNbeta illustrates the complex relationships between oncolytic ability and immunogenicity. Mol Ther. 2012;20:736–48. https://doi.org/10.1038/mt.2011.228 . PubMed PMID: 22008913; PMCID: PMC3321606.
doi: 10.1038/mt.2011.228
Lv C, Su Q, Liang Y, Hu J, Yuan S. Oncolytic vaccine virus harbouring the IL-24 gene suppresses the growth of lung cancer by inducing apoptosis. Biochem Biophys Res Commun. 2016;476:21–8. https://doi.org/10.1016/j.bbrc.2016.05.088 . PubMed PMID: 27208781.
doi: 10.1016/j.bbrc.2016.05.088
pubmed: 27208781
Guo ZS, Lotze MT, Zhu Z, Storkus WJ, Song XT. Bi- and tri-specific t cell engager-armed oncolytic viruses: next-generation cancer immunotherapy. Biomedicines. 2020;8(7):204. https://doi.org/10.3390/biomedicines8070204 . PubMed PMID: 32664210.
Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther. 2014;22:102–11. https://doi.org/10.1038/mt.2013.240 . PubMed PMID: 24135899; PMCID: PMC3978793.
doi: 10.1038/mt.2013.240
Liu Z, Ge Y, Wang H, Ma C, Feist M, Ju S, et al. Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun. 2018;9:4682. https://doi.org/10.1038/s41467-018-06954-z . PubMed PMID: 30410056; PMCID: PMC6224581.
doi: 10.1038/s41467-018-06954-z
Ekeke CN. Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease. J Thorac Cardiovasc Surg. 2020;S0022–5223(20):33337–7. Epub 2020/12/13. https://doi.org/10.1016/j.jtcvs.2020.11.160 . PubMed PMID: 33485667.
Wang BC, Zhang ZJ, Fu C, Wang C. Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Medicine Baltimore. 2019;98:e18054. https://doi.org/10.1097/md.0000000000018054 . PubMed PMID: 31764833; PMCID: PMC6882659.
doi: 10.1097/MD.0000000000018054
Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, et al. Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2019;26(4):846–54. https://doi.org/10.1158/1078-0432.ccr-19-2443 . PubMed PMID: 31676670.
doi: 10.1158/1078-0432.CCR-19-2443
pubmed: 31676670
pmcid: 7748730
Hoshino I, Gunji H, Ishige F, Iwatate Y, Takiguchi N, Ikeda A, et al. Surgical treatment strategy for esophagogastric junction cancers based on the tumor diameter. BMC Surg. 2019;19:152. https://doi.org/10.1186/s12893-019-0614-5 . PubMed PMID: 31651313; PMCID: PMC6814119.
doi: 10.1186/s12893-019-0614-5
Lei J, Li QH, Yang JL, Liu F, Wang L, Xu WM, Zhao WX. The antitumor effects of oncolytic adenovirus H101 against lung cancer. Int J Oncol. 2015;47:555–62. https://doi.org/10.3892/ijo.2015.3045 . PubMed PMID: 26081001.
doi: 10.3892/ijo.2015.3045
pubmed: 26081001
Fujiwara T. A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer. Acta Med Okayama. 2011;65:151–62. https://doi.org/10.18926/amo/46626 . PubMed PMID: 21709712.
doi: 10.18926/AMO/46626
pubmed: 21709712
Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther. 2010;18:429–34. https://doi.org/10.1038/mt.2009.262 . PubMed PMID: 19935775; PMCID: PMC2839300.
doi: 10.1038/mt.2009.262
Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma. Retrieved July 25, 2020, from https://ClinicalTrials.gov/show/NCT03921021 .
Wong J, Kelly K, Mittra A, Gonzalez SJ, Song KY, Simpson G, et al. A third-generation herpesvirus is effective against gastroesophageal cancer. J Surg Res. 2010;163:214–20. https://doi.org/10.1016/j.jss.2010.03.021 . PubMed PMID: 20538290; PMCID: PMC3266820.
doi: 10.1016/j.jss.2010.03.021
Stiles BM, Bhargava A, Adusumilli PS, Stanziale SF, Kim TH, Rusch VW, Fong Y. The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery. 2003;134:357–64. https://doi.org/10.1067/msy.2003.244 . PubMed PMID: 12947341.
doi: 10.1067/msy.2003.244
pubmed: 12947341
Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality-of-life measures of extent of disease. Chest. 2000;117:73–8. https://doi.org/10.1378/chest.117.1.73 . PubMed PMID: 10631202.
doi: 10.1378/chest.117.1.73
pubmed: 10631202
Zamboni MM, da Silva CT Jr, Baretta R, Cunha ET, Cardoso GP. Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm Med. 2015;15:29. https://doi.org/10.1186/s12890-015-0025-z . PubMed PMID: 25887349; PMCID: PMC4379612.
doi: 10.1186/s12890-015-0025-z
Krug LM, Zauderer MG, Adusumili PS, McGee E, Sepkowitz K, Klang M, et al. Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion. J Clin Oncol. 2015;33(15 Suppl):7559. https://doi.org/10.1200/jco.2015.33.15_suppl.7559 .
Iankov ID, Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB, et al. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat. 2010;122:745–54. https://doi.org/10.1007/s10549-009-0602-z . PubMed PMID: 19894113; PMCID: PMC2935656.
doi: 10.1007/s10549-009-0602-z
Weibel S, Hofmann E, Basse-Luesebrink TC, Donat U, Seubert C, Adelfinger M, et al. Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer. J Transl Med. 2013;11:106. https://doi.org/10.1186/1479-5876-11-106 . PubMed PMID: 23635329; PMCID: PMC3646671.
doi: 10.1186/1479-5876-11-106
Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther. 2010;18:251–63. Epub 2009/12/24. doi: mt2009283 [pii]. 10.1038/mt.2009.283. PubMed PMID: 20029399.
Guo ZS, Bartlett DL. Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land. Cancer Gene Ther. 2014;21:261–3. https://doi.org/10.1038/cgt.2014.31 . PubMed PMID: 25034971; PMCID: PMC4105137.
doi: 10.1038/cgt.2014.31
Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, Nelson BH. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer. 2018;18:419–32. https://doi.org/10.1038/s41568-018-0009-4 . PubMed PMID: 29695749.
doi: 10.1038/s41568-018-0009-4
pubmed: 29695749
Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, et al. Canadian Cancer Trials Group (CCTG) IND211: a randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. Lung Cancer. 2018;120:142–8. https://doi.org/10.1016/j.lungcan.2018.03.005 . PubMed PMID: 29748010.
doi: 10.1016/j.lungcan.2018.03.005
pubmed: 29748010
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients. Retrieved July 25, 2020, from https://ClinicalTrials.gov/show/NCT02879760 .
A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract. Retrieved July 25, 2020, from https://ClinicalTrials.gov/show/NCT04195373 .